Back to top

Incyte Winds Down Itacitinib Rollover Study: What Investors Should Know

Incyte ($INCY) announced an update on their ongoing clinical study. This update covers Incyte’s rollover study NCT04640025, titled “A Phase 2, Open...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Incyte Corporation (INCY)